Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer
2014 San Antonio Breast Cancer SymposiumJame Abraham, MD, FACP, of the Cleveland Clinic, offers his thoughts on abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.
Related Videos
Clifford A. Hudis, MD, FACP, on Enzalutamide in Androgen Receptor–Positive, Triple-Negative Breast Cancer
Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract P5-19-09, “
Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract S3-08,
William J. Gradishar, MD, of Northwestern University, and Edith A. Perez of the Mayo Clinic Cancer Center, discuss immunotherapy and the highlights of the BOLERO-1...
Clifford A. Hudis, MD, FACP, on the SOFT Trial
William J. Gradishar, MD, and Edith A. Perez, MD, on Immunotherapy and highlights of the Bolero-1 and SOFT Trials
Jack Cuzick, PhD, on the IBIS-I Trial
Jack Cuzick, PhD, of the Wolfson Institute of Preventive Medicine, discusses abstract S3-07,
Lisa A. Carey, MD, on Pembrolizumab in Advanced Triple-Negative Breast Cancer
Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09,
